BACKGROUND: The detection of prostate cancer (PCa) is currently based on prostate-specific antigen (PSA) quantification as an initial screening followed by ultrasound-guided transrectal biopsy. However, the high rate of false-negative biopsies often leads to inappropriate treatment. Therefore, new molecular biomarkers, such as urine microRNAs (miRNAs), are a possible way to redefine PCa diagnostics. PATIENTS AND METHODS: Urine samples of 356 patients undergoing prostate biopsy (256 cases with confirmed prostate cancer, 100 cases with negative prostate biopsy) at the Masaryk Memorial Cancer Institute (Czech Republic) and additional 36 control subjects (healthy controls, benign prostatic hyperplasia - BPH) were divided into the discovery and validation cohorts and analyzed. In the discovery phase, small RNA sequencing was performed using the QIAseq miRNA Library Kit and the NextSeq 500 platform. Identified miRNA candidates were validated by the RT-qPCR method in the independent validation phase. RESULTS: Using the small RNA sequencing method, we identified 12 urine miRNAs significantly dysregulated between PCa patients and controls. Furthermore, independent validation showed the ability of miR-501-3p and the quantitative miR-335:miR-501 ratio to distinguish between PCa patients and patients with negative prostate biopsy. The subsequent combination of the miR-335:miR-501 ratio with PSA and total prostate volume (TPV) using logistic regression exceeded the analytical accuracy of standalone parameters [area under curve (AUC)=0.75, positive predictive value (PPV)=0.85, negative predictive value (NPV)=0.51)] and discriminated patients according to biopsy outcome. CONCLUSION: Combination of miR-335:miR-501 ratio with PSA and total prostate volume was able to identify patients with negative prostate biopsy and could potentially streamline decision making for biopsy indication.

Central European Institute of Technology Masaryk University Brno Czech Republic

Central European Institute of Technology Masaryk University Brno Czech Republic;

Department of Biology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Urologic Oncology Clinic of Surgical Oncology Masaryk Memorial Cancer Institute Brno Czech Republic;

Research Unit of Non Coding RNAs and Genome Editing in Cancer Division of Clinical Oncology Department of Medicine Comprehensive Cancer Center Graz Medical University of Graz Graz Austria

Zobrazit více v PubMed

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. PubMed DOI

Descotes JL. Diagnosis of prostate cancer. Asian J Urol. 2019;6(2):129–136. doi: 10.1016/j.ajur.2018.11.007. PubMed DOI PMC

Liu J, Dong B, Qu W, Wang J, Xu Y, Yu S, Zhang X. Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone. Sci Rep. 2020;10(1):5157. doi: 10.1038/s41598-020-62015-w. PubMed DOI PMC

Nam RK, Benatar T, Amemiya Y, Seth A. MiR-139 induces an Interferon-β response in prostate cancer cells by binding to RIG-1. Cancer Genomics Proteomics. 2021;18(3):197–206. doi: 10.21873/cgp.20252. PubMed DOI PMC

Juracek J, Peltanova B, Dolezel J, Fedorko M, Pacik D, Radova L, Vesela P, Svoboda M, Slaby O, Stanik M. Genome-wide identification of urinary cell-free microRNAs for non-invasive detection of bladder cancer. J Cell Mol Med. 2018;22(3):2033–2038. doi: 10.1111/jcmm.13487. PubMed DOI PMC

Zhou J, Gong G, Tan H, Dai F, Zhu X, Chen Y, Wang J, Liu Y, Chen P, Wu X, Wen J. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. Oncol Rep. 2015;33(6):2915–2923. doi: 10.3892/or.2015.3937. PubMed DOI

Avissar M, Christensen BC, Kelsey KT, Marsit CJ. MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res. 2009;15(8):2850–2855. doi: 10.1158/1078-0432.CCR-08-3131. PubMed DOI PMC

Lewicki P, Shoag J, Golombos DM, Oromendia C, Ballman KV, Halpern JA, Stone BV, O’Malley P, Barbieri CE, Scherr DS. Prognostic significance of a negative prostate biopsy: an analysis of subjects enrolled in a prostate cancer screening trial. J Urol. 2017;197(4):1014–1019. doi: 10.1016/j.juro.2016.11.002. PubMed DOI

Serefoglu EC, Altinova S, Ugras NS, Akincioglu E, Asil E, Balbay MD. How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer. Can Urol Assoc J. 2013;7(5-6):E293–E298. doi: 10.5489/cuaj.11224. PubMed DOI PMC

Wolters T, van der Kwast TH, Vissers CJ, Bangma CH, Roobol M, Schröder FH, van Leenders GJ. False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol. 2010;34(1):35–43. doi: 10.1097/PAS.0b013e3181c3ece9. PubMed DOI

Haldrup C, Kosaka N, Ochiya T, Borre M, Høyer S, Orntoft TF, Sorensen KD. Profiling of circulating microRNAs for prostate cancer biomarker discovery. Drug Deliv Transl Res. 2014;4(1):19–30. doi: 10.1007/s13346-013-0169-4. PubMed DOI

Rodríguez M, Bajo-Santos C, Hessvik NP, Lorenz S, Fromm B, Berge V, Sandvig K, Linē A, Llorente A. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Mol Cancer. 2017;16(1):156. doi: 10.1186/s12943-017-0726-4. PubMed DOI PMC

Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microRNA Profiling of Prostate Cancer. J Cancer. 2013;4(5):350–357. doi: 10.7150/jca.6394. PubMed DOI PMC

Panigrahi GK, Ramteke A, Birks D, Abouzeid Ali HE, Venkataraman S, Agarwal C, Vibhakar R, Miller LD, Agarwal R, Abd Elmageed ZY, Deep G. Exosomal microRNA profiling to identify hypoxia-related biomarkers in prostate cancer. Oncotarget. 2018;9(17):13894–13910. doi: 10.18632/oncotarget.24532. PubMed DOI PMC

Koh Y, Bustos MA, Moon J, Gross R, Ramos RI, Ryu S, Choe J, Lin SY, Allen WM, Krasne DL, Wilson TG, Hoon DSB. Urine cell-free microRNAs in localized prostate cancer patients. Cancers (Basel) 2022;14(10):2388. doi: 10.3390/cancers14102388. PubMed DOI PMC

Zhang Z, Shao L, Wang Y, Luo X. MicroRNA-501-3p restricts prostate cancer growth through regulating cell cycle-related and expression-elevated protein in tumor/cyclin D1 signaling. Biochem Biophys Res Commun. 2019;509(3):746–752. doi: 10.1016/j.bbrc.2018.12.176. PubMed DOI